Director Orbimed Advisors LLC buys $15 million of Aspen Neuroscience, Inc. (ASPE)

Orbimed Advisors LLC, director of Aspen Neuroscience, Inc., bought 1,000,000 shares on the open market on November 2, 2026 at an average of $15.00 a share, for a total of $15 million. The purchase was reported to the SEC on Form 4 on November 4, 2026.

It raised their holding by 39%, to 3,589,132 shares.

3 other insiders also bought at least $10,000 of ASPE within 30 days, which makes this a cluster buy.

It is Orbimed Advisors LLC's first purchase of ASPE in at least 1 year of our records.

In the 12 months up to this filing, Aspen Neuroscience, Inc. insiders reported 5 open-market purchases and 0 sales.

WallStPal Score: 65 out of 100, because of raised their holding by 39%; a large purchase; first purchase in 1+ year; 3 other insiders also bought.

It is too soon to say how the stock did afterward. This page will update as prices come in.

Our read

It is one of 5 insider purchases at ASPE in the past year. It is worth reading next to the company's own results and news before drawing conclusions.

Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.

Examples

We have no earlier insider purchases of Aspen Neuroscience, Inc. with a measured result to compare against, so this purchase is the first data point. Our study of 2026 insider purchases found the typical purchase roughly kept pace with the S&P 500 over three months, with a minority doing much better.

Explain it like I'm 13

Orbimed Advisors LLC helps run Aspen Neuroscience, Inc.. Spending $15 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.

More: all ASPE insider trades · Orbimed Advisors LLC's track record